Bovine cartilage is derived from cartilage, usually the trachea, of cows. It is used to prevent and treat cancer and treat HIV/AIDS; it may be administered via oral and parenteral routes. In vitro studies suggest that bovine cartilage may have antitumor and immunoregulatory effects. Few published clinical trials demonstrate its efficacy.
Nausea and vomiting are commonly reported adverse events. Other reported effects include changes in taste perception, fatigue, dizziness, and dyspepsia. Inflammation and irritation at injection sites are common following parenteral administration.
Brand names: Catrix-S, Catrix, Psoriacin®, Rumalon®
Source: Memorial Sloan Kettering Cancer Center
This 2018 study states: It appears that BC [bovine cartilage] induces tumor cell death through apoptosis and this mechanism of action is the same across different cell lines and species. Additionally, BC appeared to be non-immunogenic.
This study states: Oral and subcutaneous administration of specific preparations of bovine tracheal cartilage rings (Catrix), a nontoxic agent, has resulted in a high response rate in 31 cases of a variety of clinical malignancies (response rate 90%, 61% complete). The demonstrated responders include present therapeutic disasters such as glioblastoma multiforme and cancers of the pancreas and lung. Other types which were treated with success included cancers of the ovary, rectum, prostate, cervix, thyroid, and an inoperable squamous cancer of the nose. These responses were observed when full dose therapy was given over prolonged courses of treatment (years).
This study states: Catrix-S is an acidic mucopolysaccharide complex derived from bovine tracheal cartilage. This material was administered by weekly subcutaneous injection (5.0-7.5 g/week) to nine patients with progressive metastatic malignancy. One complete response was seen in a patient with metastatic renal cell carcinoma to the lungs. Eight patients had progression of their disease. No undue toxicity and no consistent immunologic alteration was noted.
This study states: The antitumor efficacy of Catrix has been evaluated in the human tumor stem cell assay system using three human tumor cell lines and fresh biopsy specimens from 22 patients with malignant tumors. In vitro efficacy has been demonstrated with high dose continuous exposure Catrix, particularly against the 8226 human myeloma cell line as well as ovarian, pancreatic, colon, testicular, and sarcoma biopsy specimens.
Where can I get this treatment and more information?
Bovine cartilage is available as a food supplement.